CA2188695A1 - Pharmaceutical formulations containing a beta-lactamase inhibiting penem in combination with a beta-lactam antibiotic and their use in the treatment of bacterial infections - Google Patents

Pharmaceutical formulations containing a beta-lactamase inhibiting penem in combination with a beta-lactam antibiotic and their use in the treatment of bacterial infections

Info

Publication number
CA2188695A1
CA2188695A1 CA002188695A CA2188695A CA2188695A1 CA 2188695 A1 CA2188695 A1 CA 2188695A1 CA 002188695 A CA002188695 A CA 002188695A CA 2188695 A CA2188695 A CA 2188695A CA 2188695 A1 CA2188695 A1 CA 2188695A1
Authority
CA
Canada
Prior art keywords
beta
penem
combination
lactam antibiotic
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002188695A
Other languages
French (fr)
Other versions
CA2188695C (en
Inventor
Kenneth Coleman
Jane Elizabeth Neale
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
Kenneth Coleman
Jane Elizabeth Neale
Smithkline Beecham P.L.C.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9408164A external-priority patent/GB9408164D0/en
Priority claimed from GB9408161A external-priority patent/GB9408161D0/en
Priority claimed from GB9408162A external-priority patent/GB9408162D0/en
Priority claimed from GB9408163A external-priority patent/GB9408163D0/en
Application filed by Kenneth Coleman, Jane Elizabeth Neale, Smithkline Beecham P.L.C. filed Critical Kenneth Coleman
Priority claimed from PCT/EP1995/001546 external-priority patent/WO1995028935A1/en
Publication of CA2188695A1 publication Critical patent/CA2188695A1/en
Application granted granted Critical
Publication of CA2188695C publication Critical patent/CA2188695C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A pharmaceutical formulation comprises, in combination with a penem of formula (I), in which: R1 is hydrogen or an organic substituent group; R2 is a fused bicyclic heterocyclic ring system of general formula (a), wherein R4 and R5 are independently hydrogen or one or more substituents replacing hydrogen atoms in the ring system shown; m is 2 or 3; p is zero, 1 or 2; and R3 is hydrogen, a salt-forming cation or an ester-forming group; and the symbol = /
= indicates that the double bond may be in either the E or Z configuration;
and a pharmaceutically acceptable carrier; a .beta.-lactam antibiotic selected from the group consisting of ceftazidime, cefotaxime, amoxycillin, and piperacillin, and pharmaceutically acceptable derivatives thereof.
CA002188695A 1994-04-25 1995-04-22 Pharmaceutical formulations containing a beta-lactamase inhibiting penem in combination with a beta-lactam antibiotic and their use in the treatment of bacterial infections Expired - Fee Related CA2188695C (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
GB9408164A GB9408164D0 (en) 1994-04-25 1994-04-25 Pharmaceutical formulations
GB9408162.7 1994-04-25
GB9408161.9 1994-04-25
GB9408164.3 1994-04-25
GB9408161A GB9408161D0 (en) 1994-04-25 1994-04-25 Pharmaceutical formulations
GB9408162A GB9408162D0 (en) 1994-04-25 1994-04-25 Pharmaceutical formulations
GB9408163.5 1994-04-25
GB9408163A GB9408163D0 (en) 1994-04-25 1994-04-25 Pharmaceutical formulations
PCT/EP1995/001546 WO1995028935A1 (en) 1994-04-25 1995-04-22 Pharmaceutical formulations containing a beta-lactamase inhibiting penem in combination with a beta-lactam antibiotic and their use in the treatment of bacterial infections

Publications (2)

Publication Number Publication Date
CA2188695A1 true CA2188695A1 (en) 1995-11-02
CA2188695C CA2188695C (en) 2007-07-24

Family

ID=38325174

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002188695A Expired - Fee Related CA2188695C (en) 1994-04-25 1995-04-22 Pharmaceutical formulations containing a beta-lactamase inhibiting penem in combination with a beta-lactam antibiotic and their use in the treatment of bacterial infections

Country Status (1)

Country Link
CA (1) CA2188695C (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009114921A1 (en) * 2008-03-17 2009-09-24 Dmitrienko Gary I INHIBITORS OF CLASS B AND CLASS D β-LACTAMASES

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009114921A1 (en) * 2008-03-17 2009-09-24 Dmitrienko Gary I INHIBITORS OF CLASS B AND CLASS D β-LACTAMASES

Also Published As

Publication number Publication date
CA2188695C (en) 2007-07-24

Similar Documents

Publication Publication Date Title
IE821129L (en) Cephalosporins
MX9804107A (en) Quinoline derivatives.
AU7493187A (en) Cephalosporin compounds, processes for their preparation and antibacterial agents
MX9605149A (en) Pharmaceutical formulations containing a beta-lactamase inhibiting penem in combination with a beta-lactam antibiotic and their use in the treatment of bacterial infections.
MX9803692A (en) Tricyclic erythromycin derivatives.
GB1456144A (en) Ureido-aryl cephalosporin compounds
CA2147755A1 (en) 6-(substituted methylene) penems and intermediates
ES2001773A6 (en) Cephalosporin derivatives.
ES8104307A1 (en) 3-[(8-Carboxy-6-tetrazolo[1,5-b]pyridazinyl)-thiomethyl]-7-[2-(2-amino-4-thiazolyl)-2-methoxyimino-acetamido]-3-cephem-4-carboxylic acid
IE850475L (en) 6-(aminoacyloxymethyl) penicillanic acid 1,1-dioxides as beta-lactamase inhibitors
DE69805975T2 (en) 2-BETA-SUBSTITUTED-6-ALKYLIDENPENICILIC ACID DERIVATIVES AS BETA LACTAMASE INHIBITORS
MY104109A (en) Antibacterial 9-deoxo-9a-allyl and propargyl-9a-aza-9a-homoerythromycin a derivatives.
CA2188695A1 (en) Pharmaceutical formulations containing a beta-lactamase inhibiting penem in combination with a beta-lactam antibiotic and their use in the treatment of bacterial infections
EP0723966A4 (en) Novel cephem derivative
CA2107675A1 (en) Antibiotic carbapenem derivatives
GB9326248D0 (en) Pharmaceutical formulations
KR900005050B1 (en) 6-beta (substituted)-(s)-hydroxymethyl-penicillanic acids and derivatives thereof
PH24103A (en) Cephalosporin derivatives
TW371304B (en) Cephem compounds having antibacterial activity, their production and pharmaceutical composition
AU619395B2 (en) Cephalosporin derivatives and processes for their preparation
MX9605773A (en) Cephalosporin compounds and processes for the preparation thereof.
ES8703479A1 (en) New antibiotic penicillanic acid cpds.

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed